Auxotrophic vaccines for tuberculosis

Indira Guleria, Rachel Teitelbaum, Ruth A. McAdam, Ganjam V. Kalpana, William R. Jacobs, Barry R. Bloom

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually. It remains the largest attributable cause of death in HIV-infected individuals, responsible for 32% of deaths of HIV-infected individuals in Africa. The only currently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used vaccine in the world, being administered to approximately 100 million children each year. Although untoward effects were not seen in several studies of HIV-seropositive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCG produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCG could no longer be detected in mice receiving the auxotrophs after 16-32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCG vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged with virulent Mycobacterium tuberculosis, several of the auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCG. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.

Original languageEnglish (US)
Pages (from-to)334-337
Number of pages4
JournalNature Medicine
Volume2
Issue number3
DOIs
StatePublished - 1996

Fingerprint

Tuberculosis Vaccines
Vaccines
BCG Vaccine
Severe Combined Immunodeficiency
HIV
Mycobacterium tuberculosis
Mutagenesis
Safety
Insertional Mutagenesis
Communicable Diseases
Cause of Death
Tuberculosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Guleria, I., Teitelbaum, R., McAdam, R. A., Kalpana, G. V., Jacobs, W. R., & Bloom, B. R. (1996). Auxotrophic vaccines for tuberculosis. Nature Medicine, 2(3), 334-337. https://doi.org/10.1038/nm0396-334

Auxotrophic vaccines for tuberculosis. / Guleria, Indira; Teitelbaum, Rachel; McAdam, Ruth A.; Kalpana, Ganjam V.; Jacobs, William R.; Bloom, Barry R.

In: Nature Medicine, Vol. 2, No. 3, 1996, p. 334-337.

Research output: Contribution to journalArticle

Guleria, I, Teitelbaum, R, McAdam, RA, Kalpana, GV, Jacobs, WR & Bloom, BR 1996, 'Auxotrophic vaccines for tuberculosis', Nature Medicine, vol. 2, no. 3, pp. 334-337. https://doi.org/10.1038/nm0396-334
Guleria I, Teitelbaum R, McAdam RA, Kalpana GV, Jacobs WR, Bloom BR. Auxotrophic vaccines for tuberculosis. Nature Medicine. 1996;2(3):334-337. https://doi.org/10.1038/nm0396-334
Guleria, Indira ; Teitelbaum, Rachel ; McAdam, Ruth A. ; Kalpana, Ganjam V. ; Jacobs, William R. ; Bloom, Barry R. / Auxotrophic vaccines for tuberculosis. In: Nature Medicine. 1996 ; Vol. 2, No. 3. pp. 334-337.
@article{ce19328ee1da4867888cb28aa43e4c7a,
title = "Auxotrophic vaccines for tuberculosis",
abstract = "Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually. It remains the largest attributable cause of death in HIV-infected individuals, responsible for 32{\%} of deaths of HIV-infected individuals in Africa. The only currently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used vaccine in the world, being administered to approximately 100 million children each year. Although untoward effects were not seen in several studies of HIV-seropositive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCG produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCG could no longer be detected in mice receiving the auxotrophs after 16-32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCG vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged with virulent Mycobacterium tuberculosis, several of the auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCG. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.",
author = "Indira Guleria and Rachel Teitelbaum and McAdam, {Ruth A.} and Kalpana, {Ganjam V.} and Jacobs, {William R.} and Bloom, {Barry R.}",
year = "1996",
doi = "10.1038/nm0396-334",
language = "English (US)",
volume = "2",
pages = "334--337",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Auxotrophic vaccines for tuberculosis

AU - Guleria, Indira

AU - Teitelbaum, Rachel

AU - McAdam, Ruth A.

AU - Kalpana, Ganjam V.

AU - Jacobs, William R.

AU - Bloom, Barry R.

PY - 1996

Y1 - 1996

N2 - Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually. It remains the largest attributable cause of death in HIV-infected individuals, responsible for 32% of deaths of HIV-infected individuals in Africa. The only currently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used vaccine in the world, being administered to approximately 100 million children each year. Although untoward effects were not seen in several studies of HIV-seropositive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCG produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCG could no longer be detected in mice receiving the auxotrophs after 16-32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCG vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged with virulent Mycobacterium tuberculosis, several of the auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCG. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.

AB - Tuberculosis is responsible for the deaths of more people each year than any other single infectious disease, with greater than 7 million new cases and 2 million deaths annually. It remains the largest attributable cause of death in HIV-infected individuals, responsible for 32% of deaths of HIV-infected individuals in Africa. The only currently available vaccine for tuberculosis, bacille Calmette-Guerin (BCG) is the most widely used vaccine in the world, being administered to approximately 100 million children each year. Although untoward effects were not seen in several studies of HIV-seropositive children, the safety of live attenuated BCG vaccine in HIV-positive adults remains unknown and a matter of some concern. To obviate potential adverse affects of BCG vaccines in immunodeficient individuals, we have studied five auxotrophic strains of BCG produced by insertional mutagenesis for safety in administration to mice with severe combined immunodeficiency disease (SCID), and for protection in a susceptible strain of mice. The results indicate that viable BCG could no longer be detected in mice receiving the auxotrophs after 16-32 weeks, and that infected SCID mice survived for at least 230 days. In contrast, all SCID mice succumbed within eight weeks to conventional BCG vaccine. When susceptible BALB/c mice were immunized with auxotrophs and subsequently challenged with virulent Mycobacterium tuberculosis, several of the auxotrophs produced comparable protection against intravenous and intratracheal challenge with M. tuberculosis relative to conventional BCG. These results suggest that auxotrophic strains of BCG represent a potentially safe and useful vaccine against tuberculosis for populations at risk for HIV.

UR - http://www.scopus.com/inward/record.url?scp=0029990029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029990029&partnerID=8YFLogxK

U2 - 10.1038/nm0396-334

DO - 10.1038/nm0396-334

M3 - Article

VL - 2

SP - 334

EP - 337

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -